Gynecologic oncology
-
Gynecologic oncology · Jun 2007
Comparative StudyLaparoscopic radical hysterectomy using pulsed bipolar system: comparison with conventional bipolar electrosurgery.
To compare the efficacy, results and complications of using the pulsed bipolar system (PlasmaKinetic; Gyrus Medical, Maple Grove, MN) and conventional bipolar electrosurgery (Kleppinger bipolar forceps; Richard Wolf Instruments, Vernon Hills, IL) in laparoscopic radical hysterectomy and pelvic lymphadenectomy in the management of early invasive cervical carcinoma. ⋯ Our findings indicate that pulsed bipolar system is more effective in laparoscopic radical hysterectomy when compared with conventional bipolar electrosurgery. Pulsed bipolar system has advantage over conventional bipolar electrosurgery in less blood loss, shorter operative time, less postoperative complication and may offer an alternative option for patients undergoing laparoscopic radical hysterectomy.
-
Gynecologic oncology · Apr 2007
AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
Little is known about the function of KIT in ovarian cancer cells, despite its expression in most tumors and extensive speculation on the therapeutic value of its inhibition. This study investigated the consequences of KIT signaling on ovarian cancer cell proliferation and survival and evaluated the molecular basis of sensitivity to imatinib mesylate. ⋯ This study demonstrates that KIT transduces anti-apoptotic signals and its inhibition with imatinib may represent a valuable therapeutic strategy for sensitizing chemoresistant ovarian cancer. pAKT may provide a mechanism of resistance to imatinib that correspondingly could serve as a predictor of sensitivity to treatment.
-
Gynecologic oncology · Apr 2007
A cost-effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer.
The majority of patients with advanced epithelial ovarian cancer (EOC) will experience a recurrence after primary chemotherapy and receive second-line chemotherapy. Patients who have a disease-free interval >6 months (platinum-sensitive) will often receive multiple chemotherapy regimens. Therefore, our goal was to assess the effectiveness and medical costs of chemotherapy for platinum-sensitive patients with advanced EOC. ⋯ Second-line chemotherapy is cost-effective for patients with platinum-sensitive recurrent EOC. Due to minimal improvements in overall survival, third- and fourth-line chemotherapy are not cost-effective strategies.
-
Gynecologic oncology · Apr 2007
Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
The aim of this study was to evaluate the use of co-registered PET/CT using F-18 fluorodeoxyglucose (FDG) for surveillance and follow-up of ovarian cancer patients to detect recurrent disease. ⋯ In our experience, FDG-PET/CT has the greatest utility in settings of suspected ovarian cancer recurrence, particularly in patients with rising CA-125 levels and negative conventional imaging. FDG-PET/CT was specifically helpful in optimizing the selection of patients for site-specific treatment, including radiation treatment planning, and aided in the selection of optimal surgical candidates. The co-registered metabolic-anatomic information from combined FDG-PET/CT holds promise in replacing the single imaging procedures.
-
Gynecologic oncology · Mar 2007
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
To evaluate the feasibility and associated survival outcome of secondary cytoreductive surgery in patients with isolated lymph node recurrence of epithelial ovarian cancer. ⋯ Complete optimal secondary cytoreductive surgery for recurrent epithelial ovarian cancer presenting as isolated node metastases is achievable in the majority of cases and is associated with a favorable long-term survival outcome.